Chemomodulatory effect of neferine on DMBA-induced squamous cell carcinogenesis: Biochemical and molecular approach

A Comprehensive Review of Natural Products as Therapeutic or Chemopreventive Agents against Head and Neck Squamous Cell Carcinoma Cells Using Preclinical Models

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that arises from the epithelium lining of the oral cavity, hypopharynx, oropharynx, and larynx. Despite the advancement of current treatments, including surgery, chemotherapy, and radiotherapy, the overall survival rate of patients afflicted with HNSCC remains poor. The reasons for these poor outcomes are due to late diagnoses and patient-acquired resistance to treatment. Natural products have been extensively explored as a safer and more acceptable alternative therapy to the current treatments, with numerous studies displaying their potential against HNSCC. This review highlights preclinical studies in the past 5 years involving natural products against HNSCC and explores the signaling pathways altered by these products. This review also addresses challenges and future directions of natural products as chemotherapeutic and chemoprevention agents against HNSCC.

Evaluation of differential white blood cell count and cheek pouch epithelium in 7,12-dimethylbenza[a]anthracene hamster carcinogenesis model, managed with three phytochemicals

Objectives: Nigella sativa (NS), thymoquinone (TQ), and epigallocatechin-3-gallate (EGCG) are phytochemicals that might have antioxidant protective potentials on the hamster cheek pouch epithelium (HCPE). We aimed at evaluating and comparing the potential therapeutic outcomes of these 3 phytochemicals by analysis of peripheral white blood cells (WBCs) counts. Materials and Methods: NS whole oil, TQ and EGCG were administered before, with or after 7,12-dimethylbenza[a]anthracene (DMBA) painting the hamster left cheek pouch. Before sacrificing each animal, 2 ml of blood was withdrawn into a fine heparin-containing tube to estimate the total WBCs, lymphocytes, MID cells, and granulocytes counts by an automatic count system. All cheek pouches were surgically excised and examined with light microscope. Results: Severe epithelial dysplasia was evident after 6 weeks of DMBA administration, and when NS was given for 2 weeks followed by DMBA for 6 weeks. When NS or EGCG were given for 2 weeks then continued with DMBA for 6 weeks, mild dysplasia was seen. When DMBA was given for 6 weeks followed by NS or TQ for 6 weeks, mild dysplasia was noted. Administration of DMBA for 6 weeks resulted in significant reduction in total WBCs and lymphocytes counts compared to healthy controls. Administration of NS or TQ for 2 weeks resulted in significant elevation in lymphocytes count compared to healthy controls. Significant elevation in total WBCS and lymphocytes counts was noted when EGCG was given for 2 weeks and continued with DMBA for other 6 weeks. Similar results were noted when DMBA was given for 6 weeks followed by TQ for 6 weeks when compared to NS, DMBA or healthy controls. Discussion: The three phytochemicals showed different levels of protection against DMBA carcinogenic activity, more specifically, TQ and NS had higher therapeutic potential and might be used for treatment and/or preventive management of oral cancer in the future. Conclusion: However, further investigations are required to address the mechanism of action and feasibility of clinical application of each phytochemical.

Neferine Suppresses Experimental Colitis-Associated Colorectal Cancer by Inhibition of NF-[Formula: see text]B p65 and STAT3

Colitis is an important risk factor for the development of colorectal cancer (CRC). The inhibitory effect and the underlying mechanism of neferine on colitis-associated colorectal cancer (CA-CRC) were investigated using an azoxymethane (AOM)/dextran sulfate sodium (DSS) triggered mice model. Compared with the CA-CRC model, oral treatment of neferine (2.5 and 5.0 mg/kg) significantly inhibited the DAI scores, decreased the tumor number, and reduced the tumor size. Neferine decreased inflammatory cell infiltration and epithelial hyperplasia in colon tissues. The levels of tumor necrosis factor-[Formula: see text] (TNF-[Formula: see text], interleukin-1beta (IL-1[Formula: see text], and interleukin 6 (IL-6) in colon tissues were decreased by neferine. Furthermore, neferine significantly decreased protein expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), p-p65, and p-STAT3 in both tumor and non-tumor tissues. In addition, neferine inhibited LPS and IL-6-induced phosphorylation of both NF-[Formula: see text]B p65 and STAT3. Molecular docking demonstrated the interactions of neferine with both NF-[Formula: see text]B p65 and STAT3. In conclusion, these results suggested that neferine inhibited CA-CRC carcinogenesis possibly by regulating NF-[Formula: see text]B and STAT3. Neferine might be a lead compound for the chemoprevention of CA-CRC.